Clinical Trial Update: Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

View source ↗

Summary

Expanded access program for Zidesamtinib (NVL-520) in patients with advanced ROS1-positive solid tumors, including ROS1-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Ros1-positive Non-small Cell Lung Cancer

Drugs mentioned

• Zidesamtinib (Zidesamtinib)

Snippet

Sponsor: Nuvalent Inc. | Conditions: Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC) | Status: AVAILABLE